ROS1-Positive Non-small Cell Lung Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

ROS1-positive non-small cell lung cancer (NSCLC) is a subtype characterized by a genetic alteration involving the ROS1 gene. This gene codes for a receptor tyrosine kinase that plays a role in cell growth and proliferation. When the ROS1 gene undergoes rearrangement or fusion with another gene, it can lead to abnormal activation of the ROS1 protein, resulting in uncontrolled cell growth and cancer development. The precise cause of ROS1 rearrangements in NSCLC remains poorly understood. However, similar to other genetic changes in cancer, it is thought to occur due to random mutations or exposure to specific environmental factors like tobacco smoke or occupational hazards such as asbestos. ROS1-positive NSCLC tends to exhibit a more aggressive behavior than other NSCLC forms, associated with a higher risk of metastasis (spreading to other body parts) and a poorer prognosis. However, they are more commonly found in specific patient subgroups, such as younger individuals, never-smokers, and those with adenocarcinoma histology. Currently, ROS1 is the target of several specific tyrosine kinase inhibitors (TKIs), with only two, crizotinib and entrectinib, having received approval from the Food and Drug Administration (FDA). Crizotinib, a low molecular weight orally administered TKI, inhibits ROS1, MET, and ALK and is considered the gold standard first-line treatment with demonstrated significant efficacy for lung cancers that harbor ROS1 gene rearrangements.
• ROS1 rearrangements are relatively rare, occurring in approximately 1-2% of NSCLC cases.

Thelansis’s “ROS1-Positive Non-small Cell Lung Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential ROS1-Positive Non-small Cell Lung Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of ROS1-Positive Non-small Cell Lung Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
ROS1-Positive Non-small Cell Lung Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: ROS1-Positive Non-small Cell Lung Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: ROS1-Positive Non-small Cell Lung Cancer, ROS1-Positive Non-small Cell Lung Cancer market outlook, ROS1-Positive Non-small Cell Lung Cancer competitive landscape, ROS1-Positive Non-small Cell Lung Cancer market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)